Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients
- 1 June 2006
- journal article
- other
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (6) , 728-735
- https://doi.org/10.1136/ard.2005.045641
Abstract
Objectives: To investigate the anti-inflammatory effects of the active leflunomide metabolite A771726 (Lef-M) in combination with methotrexate (MTX) on synovial macrophages (SM) from rheumatoid arthritis (RA) patients co-cultured with an activated T cell line (Jurkat cell line). Methods: Pro-inflammatory cytokines (TNFα, IL1β, IL6), adhesion molecule ICAM-1, cyclooxygenase isoenzymes (COX1, COX2), and the nuclear factor κB (NF-κB) complex were analysed on SM co-cultured with a T cell line, as intracellular protein expression by immunocytochemistry (ICC) and western blot analysis, as extracellular protein expression by ELISA assay, and as mRNA expression by reverse transcriptase-multiplex PCR (RT-MPCR) after treatment with Lef-M (1, 10, 30 μmol/l) alone or in combination with MTX (50 ng/ml). Results: The most significant intracellular decrease in cytokines was observed by ICC in SM treated with the combination of Lef-M (1, 10, 30 μmol/l) and MTX (50 ng/ml) versus untreated SM (TNFα 29%, 37%, 49%, IL1β 56%, 43%, 50%, and IL6 59%, 62%, 71%, respectively). Furthermore, a significant decrease was confirmed concerning cytokine levels evaluated by ELISA in the medium of SM treated with the combination Lef-M+MTX (TNFα 40%, 41%, 44%; IL1β 10%, 20%, 60%; IL6 37%, 41%, 49%, respectively). Western blot and RT-PCR analysis confirmed these results. Concordant decreased expression was observed for ICAM-1, COX1, COX2, and the NF-κB complex after Lef-M+MTX treatment. Conclusions: The combination of MTX and Lef-M shows additive inhibitory effects on the production of inflammatory mediators from SM co-cultured with a T cell line. These observations might support the positive results obtained in RA clinical studies by combination therapy.Keywords
This publication has 36 references indexed in Scilit:
- Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cellsAnnals of the Rheumatic Diseases, 2004
- Synovial activation in rheumatoid arthritisFrontiers in Bioscience-Landmark, 2004
- Active leflunomide metabolite inhibits interleukin 1β, tumour necrosis factor α, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue culturesAnnals of the Rheumatic Diseases, 2003
- Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2003
- Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2001
- Leflunomide: mode of action in the treatment of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2000
- A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo‐oxygenase‐2 in vitro and in vivo in a substrate‐sensitive mannerBritish Journal of Pharmacology, 1999
- The Immunosuppressive Metabolite of Leflunomide Is a Potent Inhibitor of Human Dihydroorotate DehydrogenaseBiochemistry, 1996
- Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generationInflammation Research, 1994
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988